This week, Lilly LLY offered to buy Dermira for $1.1 billion to add the latter’s late-stage candidate for atopic dermatitis/eczema, lebrikizumab. Meanwhile, AstraZeneca AZN announced discontinuation …
More Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates Videos